Roche KRAS drug succeeds in head-to-head lung cancer study
The Phase 3 trial comparing Roche’s divarasib with treatments from Amgen and Bristol Myers in patients with non-small cell lung cancer has yielded promising results, indicating a significant advancement in targeted therapies for this challenging indication. This head-to-head study not only highlights the efficacy of divarasib but also underscores Roche’s commitment to pioneering innovative solutions…









